UNIVERSITATS-KINDERSPITAL BEIDER BASEL

Their core work

The University Children's Hospital Basel (UKBB) is a Swiss pediatric teaching hospital and clinical research center focused on diseases affecting infants, children, and adolescents. Its research contribution to H2020 sits at the intersection of pediatric infectious disease, vaccinology, and neonatal intensive care, where clinicians run trials, contribute biological samples and clinical data, and validate infection-prevention protocols in real hospital settings. UKBB is the kind of partner consortia turn to when a study needs pediatric patient cohorts, neonatal ICU access, or clinical expertise in childhood infections that adult-focused hospitals cannot provide.

What they specialise in

How they've shifted over time

In their earlier H2020 work (2016-2018 start dates), UKBB contributed to vaccine science and immune-system research, particularly around pertussis and systems vaccinology in PERISCOPE. By 2019-2021 the focus clearly shifted toward hospital-acquired infection prevention, antimicrobial resistance, and implementation science in neonatal units through NeoIPC. The trajectory moves from upstream biological/immunological research toward downstream clinical practice change and resistance containment.

UKBB is moving toward applied, clinic-embedded work on antimicrobial resistance and infection control in vulnerable pediatric populations, making them a strong fit for upcoming Horizon Europe AMR and patient-safety calls.

How they like to work

UKBB participates exclusively as a third party across all three H2020 projects, meaning they join via partner institutions rather than signing the grant directly — a common pattern for hospitals contributing clinical capacity to university-led consortia. They sit in fairly large networks (46 distinct partners across 15 countries) and bring specialized pediatric clinical assets rather than coordination capacity. Expect them to deliver patient recruitment, clinical protocols, and site-level data, not grant management.

Connected to 46 unique partners across 15 countries through just three projects, indicating embedding in substantial pan-European health consortia. Geographic spread is European with a notable Russian-European link via REACH.

What sets them apart

UKBB is one of Switzerland's dedicated children's hospitals, giving consortia something most academic medical centers cannot: a purely pediatric clinical environment with its own NICU, infectious disease service, and ethics infrastructure tuned to minors. Partner with them when your study specifically needs neonates, infants, or adolescents as a patient population — they are not a generalist hospital competing on volume, but a specialist site competing on pediatric depth. Their Swiss base also helps consortia meet geographic balance criteria outside the EU27.

Highlights from their portfolio

• PERISCOPE
  Large IMI-style pertussis vaccine consortium (Sofia ref. 115910) covering correlates of protection across Europe — a flagship vaccinology project.
• NeoIPC
  Their most recent and most clinically applied work: a cluster randomised trial designing infection-prevention interventions for resistant bacteria in NICUs across multiple countries.
• REACH
  Unusual Russian-European alliance studying HIV in women, children and adolescents — extending UKBB's network beyond standard EU partnerships.